Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy

Document Type : Case report

Authors
Ashwin Parihar 1
Apurva Sood 1
Ashwani Sood 1
Ajay Gulati 2
Bhagwant Mittal 1
1 Departments of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Radiodiagnosis, Post Graduate Institute of Medical Education and Research, Chandigarh, India
10.22038/aojnmb.2020.44324.1297
Abstract
We present the case of a 60-year-old man with metastatic neuroendocrine tumor of the ileum following ileal resection, being evaluated for 177Lu-based peptide receptor radionuclide therapy. 68Ga-DOTANOC PET/CT showed focal increased tracer uptake in the scrotal region without any morphologic changes on the corresponding CT images. Similar increased tracer uptake was seen on post-therapy whole-body imaging following 177Lu-DOTATATE therapy. An USG guided FNA revealed no malignant cells on cytopathologic examination. This case illustrates that focal testicular tracer uptake, may not always be pathological and can represent a normal physiologic variant, similar to the diffuse testicular somatostatin receptor expression as previously reported in literature.
Keywords
68Ga-DOTANOC- PET/CT
Testicular uptake
Physiologic Neuroendocrine tumor
177Lu-DOTATATE
Somatostatin receptor
DOTATOC
  1. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010; 51: 669–673.
  2. Wild D, Mäcke HR, Waser B, Reubi J C, Ginj M, Rasch H, Müller-Brand J, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005; 32:724–724.
  3. Sharma P, Dhull VS, Arora S, Gupta P, Kumar R, Durgapal P, et al. Diagnostic accuracy of 68Ga-DOTANOC PET/CT imaging in pheochromocytoma. Eur J Nucl Med Mol Imaging. 2014; 41: 494–504.
  4. Parihar AS, Mittal BR, Vadi SK, Basher RK, Bhansali A. Ectopic Cushing Syndrome (ECS). Clin Nucl Med. 2018; 43:769–770.
  5. Ashwathanarayana AG, Biswal CK, Sood A, Parihar AS, Kapoor R, Mittal BR. Imaging-guided use of combined 177Lu-DOTATATE and capecitabine therapy in metastatic mediastinal paraganglioma. J Nucl Med Technol. 2017; 45:314–316.
  6. Sharma P, Mukherjee A, Bal C, Malhotra A, Kumar R. Somatostatin Receptor–Based PET/CT of Intracranial Tumors: A Potential Area of Application for 68Ga-DOTA Peptides? Am J Roentgenol. 2013; 201:1340–1347.
  7. Parihar A S, Basher R K, Rana N, Mittal B R. Incidental Meningioma on 68Ga-DOTANOC Positron-Emission Tomography. Indian J Nucl Med. 2018; 33:182.
  8. Vadi SK, Mittal BR, Parihar AS, Kumar R, Singh H, Singh G. 68Ga-DOTANOC PET/CT in an Atypical Extraskeletal Paravertebral Hemangioma Mimicking as Neurogenic Tumor in a Known Case of Breast Cancer. Clin Nucl Med. 2019; 44:E364–E366.
  9. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008; 35:72–79.
  10. Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013; 54:364–372.
  11. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–518.
  12. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: Preliminary data. Eur J Nucl Med. 2001; 28:1751–1757.
  13. Al-Ibraheem A, Bundschuh RA, Notni J, Buck A, Winter A, Wester HJ, et al. Focal uptake of  68Ga-DOTATOC in the pancreas: Pathological or physiological correlate in patients with neuroendocrine tumours? Eur J Nucl Med Mol Imaging. 2011; 38:2005–2013.
  14. Hofman MS, Eddie Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: Clinical utility, normal patterns, pearls, and pitfalls in interpretation1. Radiographics. 2015; 35:500–516.
  15. Baou N, Bouras M, Droz JP, Benahmed M, Krantic S, et al. Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type. Carcinogenesis. 2000; 21:805–810.Kagna O, Pirmisashvili N, Tshori S, Freedman N, Israel O, Krausz Y, et al. Neuroendocrine Tumor Imaging with 68Ga-DOTA-NOC: Physiologic and Benign Variants. Am J Roentgenol. 2014; 203:1317–1323.
  16. Todorović-Tirnanić MV, Gajić MM, Obradović VB, Baum RP, et al. Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate. Cancer Biother Radiopharm. 2014; 29:108–115.
  17. Degnan AJ, Tadros SS, Tocchio S. Pediatric Neuroendocrine Carcinoid Tumors: Review of Diagnostic Imaging Findings and Recent Advances. Am J Roentgenol. 2017; 208:868–877.
  18. Carreras C, Kulkarni HR, Baum RP. Rare Metastases Detected by 68Ga-Somatostatin Receptor PET/CT in Patients with Neuroendocrine Tumors. Recent Results Cancer Res. 2013. 379–384.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 8, Issue 2
July 2020
Pages 132-135